New York Oncology Hematology | Albany, NY

Research site

(Unclaimed)

Location

400 Patroon Creek Boulevard, Albany, New York, United States of America

Site insights

Top conditions

Top treatments

Daratumumab

Niraparib

Bevacizumab

Prednisone

Pembrolizumab

Prednisone Versus Abiraterone Acetate

Abiraterone Acetate

relatlimab+nivolumab

Oprozomib

INCB001158

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 32 total trials

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus...

Enrolling

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Drug: 5-Fluorouracil

Drug: Tislelizumab

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)

The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenali...

Active, not recruiting

Multiple Myeloma

Drug: Lenalidomide

Drug: Daratumumab

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (QUEST)

The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib comb...

Active, not recruiting

Prostatic Neoplasms, Castration-Resistant

Drug: Niraparib 200 mg

Drug: Cetrelimab 480 mg

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting

Metastatic Castration-sensitive Prostate Cancer

Drug: Niraparib

Drug: Prednisone

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE)

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP...

Active, not recruiting

Castration-Resistant Prostatic Cancer

Drug: Prednisone

Drug: New Formulation of Niraparib and Abiraterone Acetate (AA)

Locations recently updated

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-em...

Enrolling

Recurrent Ovarian Cancer

Folate Receptor-Alpha Positive

Drug: Lubricating Eye Drops

Drug: Prednisolone acetate ophthalmic suspension 1% eye drops

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free sur...

Active, not recruiting

Smoldering Multiple Myeloma

Drug: Daratumumab SC: daratumumab + rHuPH20

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also kn...

Enrolling

Melanoma

Drug: fianlimab

Drug: cemiplimab